Cynosure receive FDA clearance for PicoSure as acne scar treatment

25 Jul 2014

The aesthetic manufacturer, Cynosure, has announced today that they have received FDA clearance to market PicoSure Focus for the treatment of acne scars.  The treatment uses laser technology that claims to revitalise the skin and erase imperfections in just 30 minutes.  

The aesthetic manufacturer, Cynosure, has announced today that they have received FDA clearance to market PicoSure Focus for the treatment of acne scars. 

The treatment uses laser technology that claims to revitalise the skin and erase imperfections in just 30 minutes.  

Cynosure president and CEO, Michael Davin, said, “The clearance to treat acne scarring with PicoSure represents a significant milestone in our strategy to pursue expanded indications that demonstrate the breadth of this technology.”

Whereas most lasers use a photo-thermal action (heat), PicoSure’s ultra-short pulse aims to create an intense photomechanical impact, known as PressureWave. Cynosure claims that this creates shockwaves in the dermis, generating collagen and elastin and resulting in dramatic improvements, without the associated downtime. 

“The treatment of acne scarring represents a large global market, and we
 believe that approval of PicoSure effectively positions us to capitalise on this opportunity,” said Mr Devin. 

“At the same time, we continue to pursue new FDA marketing clearances for PicoSure in additional indications such as the treatment of wrinkles,” he added.

As well as being recommended for acne scarring and revitalisation, PicoSure Focus can be used for toning, texture, wrinkles and fine lines. In 2012 it was granted FDA approval for the removal of tattoos and pigmented lesions.

Comments

Log-in to post a comment